GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. boosted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 52,537,446 shares of the company’s stock after purchasing an additional 2,155,429 shares during the period. Vanguard Group Inc. owned 0.11% of GE HealthCare Technologies worth $4,107,378,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in GEHC. Runnymede Capital Advisors Inc. acquired a new stake in shares of GE HealthCare Technologies in the 4th quarter worth about $28,000. Continuum Advisory LLC grew its position in GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares during the last quarter. Bank of Jackson Hole Trust acquired a new stake in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $32,000. OFI Invest Asset Management acquired a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $34,000. Finally, Flagship Wealth Advisors LLC acquired a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $34,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on GEHC. Citigroup boosted their price target on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. The Goldman Sachs Group raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $85.00 to $100.00 in a report on Tuesday, March 11th. Wells Fargo & Company raised their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their price target for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.75.

GE HealthCare Technologies Trading Up 0.3 %

GE HealthCare Technologies stock opened at $81.70 on Tuesday. GE HealthCare Technologies Inc. has a 1 year low of $74.51 and a 1 year high of $94.80. The firm’s 50 day moving average price is $86.94 and its two-hundred day moving average price is $85.98. The firm has a market cap of $37.36 billion, a price-to-earnings ratio of 18.87, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The company had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. On average, research analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.